Page 3 - Managed Access Program News Today

Investegate announcements from Clinigen Group plc, Clinigen signs agreement with Nippon Shinyaku

Lenzilumab is in development as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies

Investegate announcements from Clinigen Group plc, Clinigen agreement with Humanigen - Lenzilumab MAP

(0) WILLINGTON, England, April 8, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to ...

CET- Comunicado - ";ultimaHoraHtml += " " + json.lead + "";}ultimaHoraHtml += ""; document.getElementById("urgente").innerHTML = ultimaHoraHtml; } } }); WILLINGTON, England, April 8, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) an...

Global Phase 3 D-LIVR study enrollment completion planned in 2021 Peginterferon Lambda for HDV Global Phase 3 LIMT-2 study initiation planned in 2021 Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies U.S. commercial launch in January 2021 EMA decision expected in 2H21 Lambda for COVID-19 Lancet Respiratory Medicine (Feld et al, 2021) Considering strategic options to advance program Avexitide for Post-Bariatric Hypoglycemia (PBH) Positive Phase 2 PREVENT stu...

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021 News provided by Share this article Share this article PALO ALTO, Calif., March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage compan...

Article content When Alex Johnston and Ryan Fengstad heard the government of Alberta would be funding the gene therapy drug Zolgensma, they felt a weight lift off their shoulders. “We’ve gotten a lot of tough news and this past year, with Zolgensma specifically, it just felt like there have been a lot of closed doors in our faces, and it really felt like Reign was getting left behind. With this new announcement we were so excited, we were overjoyed, we were crying watching the announcement ...